Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company
focused on discovering and developing novel antibody immunotherapies
that help the immune system fight cancer and other diseases, today
announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and
Chief Executive Officer, will present at the Noble
Financial Capital Markets’ 12th Annual Investor and Equity
Conference on Wednesday, January 20, 2016 at 10:00 am Eastern Time.
In addition, Dr. Tinkelenberg will be participating in a panel
discussion entitled “The Brave New World of Cancer Immunotherapy” at
5:15 pm Eastern Time on Tuesday, January 19, 2016. The conference is
being held at the Club Med in Sandpiper Bay, FL.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these
agents, Enumeral’s researchers apply a proprietary immune profiling
technology platform that measures functioning of the human immune system
at the level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160119005611/en/
Copyright Business Wire 2016